Catherine Novack
Stock Analyst at JonesTrading
(4.64)
# 879
Out of 4,651 analysts
142
Total ratings
42.6%
Success rate
25.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Rated: Hold | n/a | $0.93 | - | 7 | Jul 31, 2026 | |
| EQ Equillium | Rated: Hold | n/a | $2.36 | - | 5 | Jul 31, 2026 | |
| FEMY Femasys | Rated: Hold | n/a | $2.29 | - | 9 | Jul 31, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $6.65 | - | 10 | Jul 30, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $97 → $85 | $84.70 | +0.35% | 17 | Jul 7, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $11 → $10 | $1.92 | +420.83% | 4 | Jun 26, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $52.64 | +156.46% | 1 | Jun 8, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $4.60 | +30.43% | 8 | Jun 2, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $35 | $5.41 | +546.95% | 14 | May 19, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $7 | $1.43 | +389.51% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $13.28 | +73.19% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $7.43 | +303.77% | 2 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.46 | - | 4 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.99 | - | 10 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $13 | $4.36 | +198.17% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $143 → $209 | $156.13 | +33.86% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $44.50 | -3.37% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $6.54 | +404.59% | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $9 | $1.56 | n/a | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $25.70 | n/a | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.6751 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 → $60 | $1.50 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.68 | n/a | 4 | Nov 15, 2021 |
Daré Bioscience
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $0.93
Upside: -
Equillium
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $2.36
Upside: -
Femasys
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $2.29
Upside: -
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $6.65
Upside: -
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: $97 → $85
Current: $84.70
Upside: +0.35%
ProQR Therapeutics
Jun 26, 2026
Maintained: Buy
Price Target: $11 → $10
Current: $1.92
Upside: +420.83%
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $52.64
Upside: +156.46%
Rezolute
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $4.60
Upside: +30.43%
Wave Life Sciences
May 19, 2026
Reiterated: Buy
Price Target: $35
Current: $5.41
Upside: +546.95%
iBio, Inc.
May 13, 2026
Maintained: Buy
Price Target: $7
Current: $1.43
Upside: +389.51%
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $13.28
Upside: +73.19%
Apr 16, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $7.43
Upside: +303.77%
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.46
Upside: -
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $16.99
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: $7 → $13
Current: $4.36
Upside: +198.17%
Feb 24, 2026
Maintained: Buy
Price Target: $143 → $209
Current: $156.13
Upside: +33.86%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $44.50
Upside: -3.37%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $6.54
Upside: +404.59%
Aug 8, 2025
Maintained: Buy
Price Target: $6 → $9
Current: $1.56
Upside: n/a
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $25.70
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $0.6751
Upside: n/a
Jun 3, 2024
Maintained: Buy
Price Target: $160 → $60
Current: $1.50
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $6.68
Upside: n/a